Eledon Pharmaceuticals (ELDN) Proxy Filing summary

Executive summary

• Annual meeting scheduled for June 10, 2025, at the company’s Irvine, CA headquarters.

• Proxy materials are available online, with options to request paper or email copies by May 30, 2025.

Voting matters and shareholder proposals

• Election of three Class II directors: Keith A. Katkin, Allan D. Kirk, and John S. McBride.

• Proposal to amend the Certificate of Incorporation to increase authorized common stock from 200,000,000 to 300,000,000.

• Proposal to amend the Certificate of Incorporation to provide for exculpation of certain officers.

• Ratification of Deloitte & Touche LLP as independent auditor for the year ending December 31, 2025.

• Board recommends a vote FOR all four proposals.

Board of directors and corporate governance

• Board slate includes three nominees for Class II director positions.